Advising for Excellence
MLTAP is a life sciences advisory practice established in 2024. It assists private equity firms in achieving their value creation objectives. This involves providing guidance on potential acquisitions or hypotheses, collaborating with the portfolio companies’ leaders, and acting as a reliable board member.
Our services
As a focused advisory firm in the Life Sciences space, we provide the following services.
Target Advisory
Upon target identification, we will engage in reviewing the pitch decks, developing detailed questions and reviewing business outlook. Additionally, we will conduct on site due diligence of the target and give an assessment on the operational and commercial synergies.
Consulting
We will work with your portfolio company's leadership team, in optimizing and or building new processes to drive improvement in the operations and commercial work streams. Additionally , we can assist in building out the leadership team through comprehensive recruiting and interviewing.
Board Services
Available to support boards as an independent director to share industry insight. We will be able to add an operational excellence perspective and help PortCo leadership teams to achieve long term shareholder value.
Our team
Dave Meadows
Founder & President
Mr. Meadows is recognized for exceling in turnarounds of departments, functions, or entire businesses. He utilizes an analytical mindset to drive process improvement through business growth initiatives and operational excellence as well as by developing connections with customers. Among his key strengths include:
Profit & Loss Responsibility | Business Growth
Account Management | Standard Work Implementation
Business Development & Expansion | Business Modeling
Strategy Development | Commercial Excellence
Mr. Meadows currently is the founder and president of MLTAP, a life sciences advisory practice founded in 2024. He partners with private equity in evaluating life science targets, driving operational excellence in portfolio companies, and serving as a trusted board member.
Prior to 2024, Mr. Meadows served as the President, CDMO Drug Substance of Cambrex, privately held by Permira. As part of the corporate leadership team, he had full P&L responsibility to grow the custom API business, including both operational and commercial teams.
Additionally he was the President, Scientific and Regulatory Review Group for WCG Clinical, owned by Leonard Green Partners, where he led the turnaround of six operating companies in the areas of Biostatistics, Expert Committees, Safety Technologies, Imaging and Pharmacovigilance.
He also held multiple leadership roles during his 14-year tenure at Thermo Fisher Scientific, where he developed and led the fast-growing Life Sciences Segment’s Advanced Engineering and Manufacturing organization. In addition, he served as VP and General Manager of Fisher BioServices business unit, helping to refocus and build the business through organic growth by supporting CDMO clients globally, including in the cell and gene therapy market.
He holds an MS and a BS in Industrial Engineering from Lehigh University.
